147 related articles for article (PubMed ID: 34914256)
1. [Prostate health index for the diagnosis of prostate cancer in Asians in Macau with a PSA level of 4－10 μg/L].
Chang KN; Hu F; Zheng W; Kwan WW; Iam-Ting IP; Shrestha S; Chan TI
Zhonghua Nan Ke Xue; 2021 Sep; 27(9):803-808. PubMed ID: 34914256
[TBL] [Abstract][Full Text] [Related]
2. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
5. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
[TBL] [Abstract][Full Text] [Related]
6. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
7. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Nandakumar V; Bornhorst JA; Algeciras-Schimnich A
Ann Clin Lab Sci; 2021 Jan; 51(1):3-11. PubMed ID: 33653775
[TBL] [Abstract][Full Text] [Related]
11. Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
Šimánek V; Vrzáková R; Viták R; Jirásko M; Fürst T; Topolčan O; Pecen L; Vurm V; Kučera R
Prostate; 2024 May; 84(7):656-665. PubMed ID: 38414098
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
13. The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and Can Be Used as Reflex Tests.
Garrido MM; Marta JC; Bernardino RM; Guerra J; Fernandes F; Pereira MH; Ribeiro R; Holdenrieder S; Pinheiro LC; Guimarães JT
Arch Pathol Lab Med; 2022 Jun; 146(6):691-700. PubMed ID: 34343237
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
[TBL] [Abstract][Full Text] [Related]
15. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D
Prostate; 2024 May; ():. PubMed ID: 38798011
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
[TBL] [Abstract][Full Text] [Related]
17. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological study on more accurate diagnosis of prostate cancer.
Kopecký J; Navláčilová V; Janoutová J; Janout V
Cent Eur J Public Health; 2020 Mar; 28(1):65-69. PubMed ID: 32228820
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.
Huang YQ; Sun T; Zhong WD; Wu CL
Am J Clin Exp Urol; 2014; 2(4):343-50. PubMed ID: 25606581
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.
Filella X; Giménez N
Clin Chem Lab Med; 2013 Apr; 51(4):729-39. PubMed ID: 23154423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
